Drug intelligence / Profile preview

Conyza blinii saponin

Development stage: Preclinical
Modality: Small Molecules

Overview

Conyza blinii saponin (CBS) is the major active fraction extracted from *Conyza blinii H.Lév.*, a natural plant distributed in southwest China. This plant is traditionally used in Chinese medicine for treating infections, inflammations, and occasionally cancers. CBS is primarily composed of triterpenoidal saponins and has demonstrated anti-cancer activity, particularly against cervical carcinoma, through the inhibition of MAPK and TGF-β signaling pathways and the modulation of Nrf2 and Reactive Oxygen Species (ROS).

Targets

NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)

Beyond the preview

Go deeper on Conyza blinii saponin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Conyza blinii saponin.

Explore the full profile